

Celgene Corporation Investor Relations Department 86 Morris Avenue Summit, NJ 07901 United States

Visit IR website ☐ Sign-up for e-mail alerts ☐

NASDAQ: CELG	
Last Trade:	74.69
Trade Time:	4:00 PM ET May 21, 2018
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	74.13 - 147.17
Volume	91,072

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

# **Company Profile**

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immuneinflammatory related diseases. Our portfolio of commercial products include REVLIMID<sup>®</sup>. VIDAZA<sup>®</sup>, THALOMID<sup>®</sup>, POMALYST®/IMNOVID®. ABRAXANE®, OTEZLA®, ISTODAX® and IDHIFA®. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... (more)

#### **Stock Performance**



### Press Releases [View all]

May 22, 2018

Celgene to Present New and Updated Data across a Range of Blood Diseases at EHA 2018

May 16, 2018

Celgene to Present New Clinical Data in
Blood Cancer and Solid Tumor Therapies at
Upcoming American Society of Clinical
Oncology (ASCO) Scientific Sessions

May 14, 2018

Celgene Corporation to Webcast at
Upcoming Investor Conferences and Events

May 4, 2018

<u>Celgene Reports First Quarter 2018</u> <u>Operating and Financial Results</u>

Apr 30, 2018

Celgene Corporation Announces Appointment of Jennifer Dudinak to Senior Vice President of Global Regulatory Affairs

### Upcoming Events [View all]

May 24, 2018 1:30 PM ET
R&D Deep Dive on Multiple Myeloma

May 30, 2018 3:00 PM ET

Bernstein Thirty-Fourth Annual Strategic

Decisions Conference 2018

## Financials [View all]

Feb 7, 2018 Annual Report (10-K)

Apr 30, 2018

Proxy Statement (DEF 14A)

May 4, 2018

Quarterly Report (10-Q)

Oct 26, 2017

Quarterly Report (10-Q)

Jul 27, 2017

Quarterly Report (10-Q)